Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: A systematic review

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 2, 2008, Pages 254-261

  van Rijen, Miranda M L ^a   Bonten, Marc ^b   Wenzel, Richard P ^c   Kluytmans, Jan A J W ^d  

^a AMPHIA HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carrier; Pre operative; Surgery

Indexed keywords

PLACEBO; PSEUDOMONIC ACID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EMBASE; ERADICATION THERAPY; HOSPITAL INFECTION; HUMAN; INFECTION RATE; MEDLINE; META ANALYSIS; NONHUMAN; POSTOPERATIVE INFECTION; PREOPERATIVE CARE; PROPHYLAXIS; RANDOMIZATION; REVIEW; STAPHYLOCOCCUS AUREUS; SURGICAL PATIENT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRANASAL; ANTIBIOTIC PROPHYLAXIS; CARRIER STATE; HUMANS; MUPIROCIN; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 38349143980     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm480     Document Type: Review

References (43)

1. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004. Am J Infect Control 2004; 32: 470-85.
2. Noskin GA, Rubin RJ, Schentag JJ et al The burden of Staphylococcus aureus on hospitals in the United States: An analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch. Intern Med 2005; 165: 1756-61.
3. Pittet D, Hugonnet S, Harbarth S et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000; 356: 1307-12.
4. Von Eiff C, Becker K, Machka K et al. Nasal carriage as a source of Staphyloccus aureus bacteremia. Study Group. N Engl J Med 2001; 344: 11-6.
5. Wertheim HFL, Vos MC, Ott A et al. Risk and outcome of nosocomial Staphylocoocus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004; 364: 703-5.
6. Kluytmans JAJW, Mouton JW, Ijzerman EPF et al. Nasal carriage of S. aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 1995; 171: 216-9.
7. Kalmeijer MD, Van Nieuwland-Bollen E, Bogaers-Hofman D et al. Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery. Infect Control Hosp Epidemiol 2000; 21: 319-23.
8. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylocoocus aureus: Epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10: 505-20.
9. Mangram AJ, Horan TC, Pearson ML et al. The Hospital Infection Control Practices Advisory Committee Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol 1999; 20: 250-78.
10. Gemaat-van der Sluis AJ, Hoogenboom-Verdegaal AM, Edixhoven PJ et al Prophylactic mupirocin could reduce orthopedic wound infections: 1,044 patients treated with mupirocin compared with 1,260 historical controls. Acta Orthop Scand 1998; 69: 412-4.
11. Kluytmans JAJW, Mouton JW, VandenBergh MFQ et al. Reduction of surgical site infections in cardiothoracic surgery by elimination of nasal carriagei of S. aureus. Infect Control Hosp Epidemiol 1996; 17: 780-5.
12. Kalmeijer MD, Coertjens H, van Nieuwland-Bollen E et al. Surgical site infections in orthopedic surgery: The effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin Infect Dis 2002; 35: 353-8.
13. Perl TM, Cullen JJ, Wenzel RP et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002; 346: 1871-7.
14. Critchley IA. Eradication of MRSA nasal colonization as a strategy for infection prevention. Drug Discov Today: Ther Strat 2006; 3: 1139-95.
15. Francois P, Pittet D, Bento M et al. Rapid detection of methicillin-resistant Staphytococcus aureus directly from sterile or non-sterile clinical samples by a new molecular assay. J Clin Microbiol 2003; 41: 254-60.
16. Paule SM, Pasquariello AC, Hacek DM et al. Direct detection of Staphylococcus aureus from adult and neonate nasal swab specimens using real-time polymerase chain reaction. J Mol Diagn 2004; 6 191-6.
17. Kallen AJ, Wilson CT, Larson RJ. Perioperative intranasal mupirocin for the prevention of surgical-site infections: Systematic review of the literature and meta-analysis. Infect Control Hosp Epidemiol 2005; 26: 916-22.
18. Laupland KB, Conly JM. Treatment of Staphyloooocus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: An evidence-based review. Clin Infect Dis 2003; 37 933-8.
19. Horan TC, Gaynes RP, Martone WJ. CDC definitions of nosocomial surgical site infections: A modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992; 13: 606-8.
20. The Cochrane Collaboration. Downloads, FICT checklist. http:// www.cochrane.nl/index.html (6 December 2007, date last accessed).
21. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Slat Med 2002; 21: 1539-58.
22. Higgins J, Thompson S, Deeks J et al. Measuring inconsistency. in meta-analyses. Br Med J 2003; 327: 557-60.
23. Garcia AM, Villa MV, Escudero ME et al. Use of nasal mupirocin for Staphylacoccus aureus: Effect on nasal carriers and-nosocomial infections. Biomedica 2003; 23: 173-9.
24. Konvalinka A, Errett L, Fong IW. Impact of treating Staphylococcus aureus nasal carriers on wound infections in cardiac surgery. J Hosp Infect 2006; 64: 162-8.
25. Cimochowski GE, Harostock MD, Brown R et al. Intranasal mupirocin reduces stemal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thorac Surg 2001; 71: 1672-9.
26. Nicholson MR, Huesman L. Controlling the usage of intranasal mupirocin does impact the rate of Staphylococcus aureus deep stemal wound infections in cardiac surgery patients. Am J Infect Control 2006; 34: 44-8.
27. Talon D, Rouget C, Cailleaux V et al. Nasal carriage of Staphylococcus aureus and cross-contamination in a surgical intensive care unit: Efficacy of mupirocin ointment. J Hosp Infect 1995; 30: 39-49.
28. Wilcox MH, Hall J, Pike H et al. Use of perioperative mupirocin to prevent methicillin-resistant Staphylococcus aureus (MRSA) orthopaedic surgical site infections. J Hosp Infect 2003; 54 196-201.
29. Yano M, Dold Y, Inoue M et al. Preoperative intranasal mupirocin ointment significantly reduces postoperative infection with Staphylocccus aureus in patients undergoing upper gastrointestinal surgery. Surg Today 2000; 30: 16-21.
30. Desai D, Desai N, Nightingale P et al. Cardage of methicillin-resistant Staphylococcus aureus is associated with an increased risk of infection after liver transplantation. Liver Transpl 2003; 9: 754-9.
31. Usry GH, Johnson L, Weems J et al. Process improvement plan for the reduction of sternal surgical site infections among patients undergoing coronary artery bypass graft surgery. Am J Infect Control 2002; 30: 434-6.
32. Paterson DL, Rihs JD, Squier C et al. Lack of efficacy of mupirocin in the prevention of infections with Staphybooccus aureus in liver transplant recipients and candidates. Transplantation 2003; 75: 194-8.
33. Martorell C, Engelman R, Corl A et al. Surgical site infections in cardiac surgery: An 11-year perspective. Am J Infect Control 2004; 32: 63-8.
34. Suzuki Y, Kamigaki T, Fujino Y et al. Randomized clinical trial of preoperative intranasal mupirocin to reduce surgical-site infection after digestive surgery Br J Surg 2003; 90: 1072-5.
35. Czamecki DB, Nash CG, Bohl M. The use of mupirocin before skin surgery. Int J Dermatol 1991; 30: 218-9.
36. Mody L, Kauffman CA, McNeil SA. Mupirocin-based decolonization of Staphylocoocus aureus carriers in residents of 2 long-term care facilities: A randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37: 1467-74.
37. Becker K, Lubritz G, Gosheger G. Efficacy of intranasal mupirocin on nasal carriage to prevent subsequent Staphyiococcus aureus infections. In: Abstracts of the Forty-filth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract K-553, p. 314. American Society for Microbiology, Washington, DC, USA.
38. Kluytmans JA, Wertheim HF. Nasal carriage of Staphylococcus aureus and prevention of nogocomial infections. Infection 2005; 33: 3-8.
39. Reagan DR, Doebbeling BN, Pfaller MA et al. Elimination of coincident Staphylocoocus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Interem Med 1991; 114: 101-6.
40. Hudson IRB. The efficacy of intranasal mupirocin in the prevention of staphylococcall infections: A review of recent experience. J Hosp Infect 1994; 27: 81-98.
41. Fawley WN, Parnell P, Hall J et al. Surveillance for mupirocin resistance following introduction of routine peri-operative prophylaxis with nasal mupirocin. J Hosp Infect 2006; 62: 327-32.
42. VandenBergh MFG, Kluytmans JAJW, Van Hout BA et al. Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery. Infect Control Hosp Epidemiol 1996; 17 786-92.
43. Young LS, Winston LG. Preoperative use of mupirocin for the prevention of healthcare-associated Staphylococcus aureus infections: A cost-effectiveness analysis. Infect Control Hosp Epidemiol 2006; 27: 1304-12.